Cancer Anorexia Market
DelveInsight’s ‘Cancer Anorexia - Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the cancer anorexia, historical and forecasted epidemiology as well as the cancer anorexia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The cancer anorexia market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM cancer anorexia market size from 2018 to 2030. The report also covers current cancer anorexia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2018–2030
Cancer Anorexia Disease Understanding and Treatment Algorithm
Cancer Anorexia Overview
Cancer is the second leading cause of death worldwide. Toward the end of life, individuals with cancer experience a substantial symptom burden. The top three common symptoms in patients with cancer at the end of life are fatigue, pain, and anorexia (appetite loss). Anorexia is the lack or loss of appetite or desire to eat leading to reduced intake; associated with metabolic derangements, including the release of proinflammatory cytokines such as interleukin (IL)-1, IL-6, and tumor necrosis factor-alpha produced by the immune system and tumor cells. It is the most common cause of decreased nutrient intake that triggers malnutrition and muscle wasting.
The causes of anorexia can be characterized by a negative protein and energy balance driven by a variable combination of reduced food intake and abnormal metabolism. It is often associated with an elevated basal metabolic rate, despite a decrease in physical activity and total energy expenditure. Muscle atrophy results from a decrease in protein synthesis and an increase in protein degradation, or a combination of both. There are numerous causes, which can be conveniently categorized as being due to central or peripheral mechanisms. Peripheral causes can be directly due to tumors causing dysphagia or directly impinging on gastrointestinal function; tumor producing substances that alter food intake, e.g., lactate, tryptophan, or parathormone-related peptide; tumors leading to alterations in nutrients resulting in the condition, e.g., zinc; or tumors producing inflammation leading to cytokine release. On the other hand, central causes of anorexia can be depression, pain, or various alterations in central neurotransmitters.
The anorexia and accompanying weight loss may occur at any stage of illness with variable severity, and it may be related to several causal factors. Symptoms that interfere with food intake include early satiety taste alterations, smell alterations, meat aversion, and nausea/vomiting. Thus, it contributes to the development of malnutrition and cachexia since it reduces the oral intake of calories, thus promoting skeletal muscle wasting. This effect is more dramatic than in simple starvation because energy expenditure is often increased.
Cancer Anorexia Diagnosis
Cancer anorexia remains one of the most prevalent and troublesome clinical problems experienced by patients with cancer during and after therapy. In general, the condition’s presence is clinically diagnosed when cancer patients refer to any negative change of their appetite. However, more symptoms such as reduction of appetite, early satiety, changes in taste, changes in odor, depression, dysphagia, painful swallowing, assessment of meal size, assessment of taste and odor are essential to diagnose the condition.
Cancer Anorexia Treatment
Several pharmacological and nutritional approaches have been used for the treatment of cancer anorexia. Keeping in mind that both anorexia and metabolic disturbances are involved, the development of different therapeutic strategies has focused on two major factors, namely, improving appetite and neutralizing metabolic disturbances. Current pharmacological agents can be divided into three categories: orexigenic agents (appetite stimulants), anti-catabolic (anti-metabolic and anti-cytokine) agents, and anabolic agents (primarily hormonal). Progestagens (megestrol acetate and medroxyprogesterone acetate) are the first-line therapy for cancer anorexia and cachexia. They are highly effective in relieving the symptoms of cancer anorexia. Corticosteroids, mainly dexamethasone, are also widely used to improve appetite in patients with cancer anorexia, however, they are associated with significant side effects. Cannabis such as dronabinol and nabilone have long been recognized to improve appetite, decrease nausea, and enhance food taste. Furthermore, cancer treatment not only decreases the appetite but makes the patient full more quickly when eating. Therefore, apart from these therapeutic agents, patients are recommended dietary changes to effectively cope and manage appetite loss during cancer treatment.
Cancer Anorexia Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incidence Cases of Anorexia by Cancer Types in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2018 to 2030.
This section provides glimpse of the Cancer Anorexia epidemiology in the 7MM.
- The total incident cases of anorexia by cancer types in the seven major markets was estimated to be 740,055 in 2020.
- The total incident cases of anorexia by cancer types in the 7 MM is expected to increase at a CAGR of 1.1% during the forecast period 2021–2030.
- In the United States, the incidence population of anorexia by cancer types was 265,539 in 2020.
- In 2020, the incident cases of cancer anorexia in advanced cancers, namely, colorectal cancer, lung cancer, pancreatic cancer, head and neck cancer, gastroesophageal cancer, and liver cancer in the US were 41,812, 140,931, 31,260, 13,416, 16,268 and 21,852, respectively.
- In the EU5 countries, the incident population of anorexia by cancer types was maximum in Germany with 72,040 cases, followed by the France with 58,419 cases in 2020. While, Spain accounted for the lowest incident population of the indication with 36,474 cases in 2020.
- As per Delvelnsight’s analysis, Japan had 197,803 incident cases of anorexia by cancer types in 2020.
Country-wise Cancer Anorexia Epidemiology
The epidemiology segment also provides the Cancer Anorexia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Cancer Anorexia Drug Chapters
The drug chapter segment of the Cancer Anorexia report encloses the detailed analysis of cancer anorexia mid and late stage pipeline drugs. It also helps to understand the Cancer Anorexia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.
Cancer Anorexia Emerging Drugs
Adlumiz/Edolmizu: Helsinn Healthcare
Adlumiz (anamorelin HCl/ONO-7643/ANAM/Edolmizu) is a selective, novel, orally active ghrelin receptor agonist. Ghrelin is an endogenous peptide primarily secreted by the stomach. Upon binding to its receptor, ghrelin stimulates multiple pathways in the positive regulation of body weight, muscle mass, appetite, and metabolism. Anamorelin has shown effects in increasing body weight and muscle mass, as well as appetite in patients with cancer cachexia. Currently, the drug is in the Phase III stage of clinical development for the treatment of malignancy-associated weight loss and anorexia in adult patients with advanced NSCLC, which was initiated in March 2019.
Product details in the report…
ART27.13: Artelo Biosciences
ART27.13 (formerly known as NEO1940 and AZD1940) is a highly potent, peripherally restricted synthetic, dual G-Protein Coupled Receptor (GPCR) agonist believed to target peripheral CB1/CB2 receptors, which has the potential to increase appetite and food intake. Originally developed by AstraZeneca, ART27.13 has been in five Phase I clinical studies, including over 200 subjects, where it demonstrated a statistically significant and dose-dependent increase in body weight in healthy subjects. Currently, the drug is clinic-ready for a Phase Ib/IIa study in anorexia associated with cancer.
Product details in the report…
NGM120: NGM Biopharmaceuticals
NGM120 is a first-in-class antagonistic antibody that binds glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) and inhibits growth differentiation factor 15 (GDF15) signaling for the potential treatment of cancer and cancer anorexia/cachexia syndrome (CACS). In preclinical studies of NGM120, it has been demonstrated that blocking the interaction between GFRAL and GDF15 is able to both reduce tumor-associated weight loss and slow tumor growth and could potentially provide a novel treatment for CACS and cancer. Following the successful completion of a Phase I safety, tolerability, and pharmacokinetics study of NGM120 in healthy adult subjects in 2019, the drug is currently in a Phase Ia/Ib study.
Product details in the report…
The treatment of anorexia related to cancer focuses on improving the appetite and neutralizing the metabolic disturbances. Current pharmacological agents can be categorized as orexigenic agents (appetite stimulants), anti-catabolic (anti-metabolic and anti-cytokine) agents, and anabolic agents (primarily hormonal).
Progestagens (megestrol acetate and medroxyprogesterone acetate) are often used as the first-line therapy for cancer anorexia and cachexia. Additionally, the US FDA approved Megestrol to treat anorexia and weight loss in patients with AIDS in 1993. Corticosteroids, mainly dexamethasone, are widely used to improve appetite in patients with cancer anorexia, however, they are associated with significant side effects, including gastrointestinal bleeding, oral candidiasis, and proximal myopathy. Other than corticosteroids and progestogens, there are certain less frequently prescribed medications for improving cancer-related anorexia, which includes NSAIDs, Omega 3 fatty acids, and cannabis.
The current market of cancer anorexia is dominated by off-label treatments, which are not very effective in providing relief to the patients and cannot be used in the long-term because of their various side-effects. Moreover, the emerging pipeline of cancer anorexia is quite weak, with three promising lead candidates in the late and early stages of development. The candidates with promising results include Anamorelin HCl (Adlumiz, ONO-7643 and ANAM), ART27.13, and NGM120 by potential key players Helsinn Healthcare, Artelo Biosciences, and NGM Biopharmaceuticals, respectively.
This section includes a glimpse of the Cancer Anorexia 7MM market.
- The market size of Cancer Anorexia in the seven major markets was estimated to be USD 313.52 Million in 2020, which is expected to show a positive growth at a CAGR of 10.92% during the study period 2018–2030.
- The United States accounts for the largest market size of USD 133.71 Million in 2020 of Cancer Anorexia throughout the study period of 2018–2030, in comparison to EU5 (Italy, Germany, France, Spain, the UK) and Japan, respectively.
- Among the EU5 countries, Germany had the highest market size with USD 27.36 Million in 2020, while Spain had the lowest market size with USD 13.74 Million in 2020.
- The Japan Cancer Anorexia market accounted for USD 75.10 Million in 2020.
The United States Market Outlook
This section provides the total Cancer Anorexia market size and market size by therapies in the United States.
EU-5 Market Outlook
The total Cancer Anorexia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Cancer Anorexia market size and market size by therapies in Japan are provided.
Cancer Anorexia Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Cancer Anorexia market or expected to get launched in the market during the study period 2018–2030. The analysis covers cancer anorexia market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Cancer Anorexia Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Cancer Anorexia emerging therapies.
Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the Cancer Anorexia market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Cancer Anorexia, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
- Comprehensive insight has been provided into the Cancer Anorexia epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Cancer Anorexia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of Cancer Anorexia market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Cancer Anorexia market.
- In the coming years, Cancer Anorexia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Cancer Anorexia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Positive results by major key players NGM Biopharmaceuticals, Artelo Biosciences and Helsinn Healthcare may increase market size in the coming years, assisted by an increase in Cancer Anorexia incident population pool.
- Currently, corticosteroids have been recommended in professional guidelines and have been associated with some improvement in appetite. Progestagens have also demonstrated an improved appetite in patients at various phases of care in multiple research studies and systematic reviews. Thus, steroid medication like dexamethasone and progesterone hormone-like medication like megestrol acetate are the most frequently used pharmacological drugs to stimulate appetite and improve weight.
- Additionally, as per PMR interviews, the prescription pattern of these medications vary in different regions, for instance, progestogens are considered as the first line treatment while corticosteroids are less frequently prescribed within the United States. The use of corticosteroids are limited in this region due to the high rate of adverse events associated with long term usage of this therapy along with the fact that the drug fails to increase the appetite after few months.
- Emerging candidate, Anamorlin has higher chances of success in the near future as the other pipeline therapies, namely ART27.13 and NGM120 are still under the early phases of development. They will require few years to be investigated and launched in the market as potential therapeutic treatment options for cancer anorexia.
Cancer Anorexia Report Insights
- Patient Population
- Therapeutic Approaches
- Cancer Anorexia Pipeline Analysis
- Cancer Anorexia Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Cancer Anorexia Report Key Strengths
- Ten Years Forecast
- 7MM Coverage
- Cancer Anorexia Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Cancer Anorexia Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- What was the Cancer Anorexia market share (%) distribution in 2018 and how it would look like in 2030?
- What would be the Cancer Anorexia total market size as well as market size by therapies across the 7MM during the forecast period (2021–2030)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest Cancer Anorexia market size during the forecast period (2021–2030)?
- At what CAGR, the Cancer Anorexia market is expected to grow at the 7MM level during the forecast period (2021–2030)?
- What would be the Cancer Anorexia market outlook across the 7MM during the forecast period (2021–2030)?
- What would be the Cancer Anorexia market growth till 2030 and what will be the resultant market size in the year 2030?
- How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
- What is the disease risk, burden and unmet needs of Cancer Anorexia?
- What is the historical Cancer Anorexia patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
- What would be the forecasted patient pool of Cancer Anorexia at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Cancer Anorexia?
- Out of the above-mentioned countries, which country would have the highest incident population of Cancer Anorexia during the forecast period (2021–2030)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the treatment of Cancer Anorexia along with the approved therapy?
- What are the current treatment guidelines for the treatment of Cancer Anorexia in the US and Europe?
- What are the Cancer Anorexia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Cancer Anorexia?
- How many therapies are developed by each company for the treatment of Cancer Anorexia?
- How many emerging therapies are in the mid-stage and late stage of development for the treatment of Cancer Anorexia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cancer Anorexia therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cancer Anorexia and their status?
- What are the key designations that have been granted for the emerging therapies for Cancer Anorexia?
- What are the 7MM historical and forecasted market of Cancer Anorexia?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Cancer Anorexia.
- To understand the future market competition in the CANCER ANOREXIA market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Cancer Anorexia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for Cancer Anorexia market.
- To understand the future market competition in the Cancer Anorexia market.